New radiation approach aims to improve sarcoma surgery outcomes
NCT ID NCT07250334
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new type of radiation called carbon ion radiotherapy given before surgery for soft tissue sarcoma. The goal is to see if it is safe and can reduce wound problems after surgery while better controlling the tumor. About 60 adults with sarcoma that can be removed will take part. The treatment involves eight radiation sessions over two weeks, followed by surgery six to eight weeks later.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 60 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Nov 2025
An estimate. Start dates often move.
- Expected to finish
-
Sep 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
19 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adults aged 19 years or older. * Histologically confirmed soft tissue sarcoma deemed suitable for curative resection. * Determined by the Yonsei Cancer Center sarcoma multidisciplinary team that preoperative carbon-ion radiotherapy followed by surgery is appropriate, considering tumor histologic subtype, size, and location. * Eastern Cooperative Oncology Group (ECOG) performance status 0-1 or Karnofsky Performance Status (KPS) ≥ 70. * Adequate organ function (including hematologic, hepatic, and renal function) suitable for radiotherapy and surgery. * Voluntarily provided written informed consent. Exclusion Criteria: * Presence of distant metastases. * Inability to plan carbon-ion radiotherapy due to metallic implants or other factors at the tumor site. * History of prior radiotherapy to the same anatomical region. * Presence of other serious medical conditions or active infections that, in the investigator's judgment, could interfere with study participation. * Presence of active implanted electronic devices (e.g., pacemaker or defibrillator) without established safety for carbon-ion radiotherapy. * Pregnant or breastfeeding women.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Soft tissue sarcoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Yonsei Cancer Center, Yonsei University College of Medicine, Yonsei University Health System
Seoul, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a dual immune antibody plus radiation shrink metastatic sarcoma?
- Can a Marine-Derived drug slow advanced soft tissue sarcoma?
- Can a One-Two punch of immunotherapy and radiation tame sarcoma before surgery?
- Can a radioactive antibody light up hidden tumors?
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Could a massive tissue bank unlock sarcoma's secrets?